Anti-Cytokeratin 14 for IHC / CK14 / KRT14, clone MSVA-614R

Antibody in 1X PBS with 0.05% BSA, 0.05% sodium azide. Cytokeratin 14 (KRT14) is a type I intermediate filament protein expressed predominantly in the basal layer of stratified epithelia, where it plays a critical role in maintaining structural integrity and supporting epithelial stem and progenitor cell populations. Cytokeratin 14 Antibody for IHC is widely used to detect KRT14 expression in formalin-fixed, paraffin-embedded tissues, enabling detailed analysis of basal cell distribution, epithelial organization, and tissue regeneration. Cytokeratin 14 antibody, also known as KRT14 antibody or CK14 antibody, is a well-established marker of basal epithelial cells in squamous and glandular tissues.KRT14 is typically co-expressed with keratin 5 in basal epithelial cells of tissues such as skin, esophagus, cervix, and urothelium, where it defines the proliferative compartment responsible for epithelial renewal. Its expression is tightly restricted to basal layers and is absent in differentiated suprabasal cells, providing a clear contrast with markers such as Cytokeratin 13 that label more differentiated epithelial compartments. This distinct layer-specific distribution makes Cytokeratin 14 a key marker for evaluating epithelial hierarchy and basal cell biology.This Cytokeratin 14 Antibody for IHC incorporates clone MSVA-614R, a monoclonal antibody evaluated using tissue microarray (TMA) analysis across a broad spectrum of normal and cancer tissues. TMA data demonstrate highly consistent cytoplasmic staining restricted to basal epithelial cells across multiple tissue types, with minimal background in non-epithelial or stromal compartments. The large-scale TMA approach enables direct comparison of KRT14 expression patterns across diverse tissues and disease states within a standardized experimental framework.In immunohistochemistry, Cytokeratin 14 antibody staining appears as strong cytoplasmic HRP-DAB brown signal confined to basal cell layers, with sharp delineation from suprabasal epithelial cells and surrounding non-epithelial tissues. TMA-based cancer panels further demonstrate robust KRT14 expression in squamous cell carcinomas and basal-like tumor populations, where staining highlights proliferative tumor compartments, while most non-squamous malignancies, including adenocarcinomas and many glandular tumors, show little to no staining. This differential expression provides clear contrast for identifying basal cell phenotype and squamous lineage.The detection of KRT14 is particularly valuable in studies of epithelial development, regeneration, and disease progression, as expansion or disruption of basal cell populations is a hallmark of dysplasia and carcinoma development in stratified epithelia. Changes in staining distribution and intensity can therefore provide insight into alterations in epithelial organization and tumor biology.Overall, Cytokeratin 14 antibody reagents provide reliable and specific detection of KRT14 in basal epithelial cells, supporting immunohistochemical analysis of epithelial structure, basal cell identity, and disease-associated alterations in stratified epithelial tissues, with strong validation across tissue microarray datasets.This antibody is part of a broader Cytokeratin 14 antibody collection supporting basal epithelial cell analysis and tissue differentiation studies.This antibody is also part of a broader collection of IHC antibodies validated by tissue microarray analysis, supporting consistent staining across normal and cancer tissues.